What Most Influences IVF Success?

Medically reviewed on 25 October 2026 - Dr. Senai Aksoy
Dr. Senai Aksoy in scrubs beside an EmbryoScope time-lapse incubator in an IVF laboratory; the embryo image on the screen is blurred

Key Takeaways

IVF results depend on several linked factors. Age when the eggs are used matters, and so do the ovarian response, the embryo and sperm, the uterus, and how well the plan fits the diagnosis. A clinic's success rate describes a group of patients, not your own chance. Before an extra test or treatment, ask who it was studied in, what outcome was counted, and how strong the evidence is.

Key evidence: ACOG/ASRM: Female age-related fertility decline (Committee Opinion 589) SART: Patient guide to ART success rates ESHRE: Good practice recommendations on add-ons in reproductive medicine

People often look for one number, or one extra step, that will decide an IVF cycle.

There is no single secret. Several factors work together, and none of them should be read on its own.

Age and ovarian reserve

Age at the time the eggs are used is a major factor in IVF results. Fertility declines gradually from about age 32 and faster after 37 (ACOG/ASRM, 2014). Age is also linked to the number of eggs that may be collected and to the chance of a chromosome problem in the embryo: the share of chromosomally normal embryos falls as maternal age rises (Gao et al., 2023).

Ovarian reserve tests help estimate how the ovaries may respond to stimulation. The two usual tests are a blood test for anti-Müllerian hormone (AMH) and the antral follicle count. That count is the number of small follicles seen on ultrasound. These tests do not measure egg quality. They should not be used on their own to predict pregnancy or live birth. Live birth means a baby born alive, not only a positive pregnancy test. The American Society for Reproductive Medicine (ASRM) advises reading them alongside age, diagnosis, past treatment, and past response (ASRM, ovarian reserve guidance).

Embryo and sperm biology

Embryo grade describes how an embryo looks. It does not show whether the chromosomes are normal. Better grades go with higher rates of normal chromosomes on average, but an embryo with a good grade can still have a chromosome abnormality (Gao et al., 2023; Baltaci et al., 2006).

Grading gives the laboratory useful information about morphology, meaning the embryo’s appearance. That includes the developmental stage, the inner cell mass (the cells that can become the fetus), and the trophectoderm (the cells that can become the placenta) (ASRM, embryo grading scales). It remains a visual assessment, and an embryo that looks less favourable may still implant.

A semen analysis looks at sperm concentration, motility (movement), and shape. These results help the team judge how much a male factor contributes. Sperm DNA integrity may be relevant in selected situations, but the AUA/ASRM guideline advises against routine DNA fragmentation analysis in the initial evaluation of a couple (AUA/ASRM guideline, part I). What any result means depends on the couple’s history and the clinical question.

Matching treatment to the case

The plan is adjusted to the medical picture and to the response seen during the cycle. The discussion may include:

The same caution applies to IVF add-ons, the extra tests and treatments offered on top of standard IVF. The European Society of Human Reproduction and Embryology (ESHRE) has published good-practice recommendations on add-ons. Before an add-on is considered, patients should be told what is known about its safety and its chance of improving live birth. Evidence varies from one add-on to another. Being commercially available does not make an add-on a routine part of treatment (ESHRE add-on recommendations). Comfort from acupuncture or herbal remedies is not the same as evidence of more live births. If you are planning another cycle, ways to improve IVF success sets out the order of decisions.

How to read clinic success rates

A clinic average is a group figure, not a personal forecast.

Published figures are still useful for comparison if you ask the right questions about them (SART). Overall averages depend heavily on patient mix: age, diagnosis, and case complexity.

Compare rates by age group, treatment type, and how the outcome is defined. A rate per embryo transfer is not the same as a rate per started cycle. Neither is the same as a cumulative live-birth rate, which counts live births from all the transfers that follow one egg collection. Our IVF success-rate methodology explains the context used on this site.

Dr. Aksoy’s Approach

Dr. Aksoy’s approach: After a previous cycle, the treatment history is usually what changes my plan. It shows where the process actually stalled: ovarian response, egg maturity, fertilisation, embryo development, or implantation. Before a first cycle, female age and ovarian reserve still decide a great deal. One failed cycle does not, by itself, justify extra tests or treatments. First identify a specific problem. Then ask whether the proposed extra has evidence of benefit — ideally for live birth — in a comparable patient group. Many add-ons raise cost and complexity without a shown benefit. The useful question is not “What can we add?” It is “What obstacle have we actually found, and could this treatment reasonably correct it?”

Frequently Asked Questions for Dr. Aksoy

Does IVF work if the woman is infertile?

Yes. Helping couples who have difficulty conceiving naturally is what IVF is for. What matters is why the woman has not conceived.

In a woman whose tubes are blocked, for example, IVF can be quite effective, because we fertilise the egg in the laboratory and remove the need for the tubes. We can also get good results in women with ovulation disorders. The situation is different if ovarian reserve is very low or the woman is older. IVF cannot turn back the clock: it does not restore the number of eggs or their chromosomal quality. Some uterine problems may also need to be assessed before transfer.

I tell my patients that an infertility diagnosis, on its own, does not mean IVF will fail. The real question is what is blocking pregnancy and how far IVF can get around that obstacle. That is why I assess the chance of success from the woman’s age, her ovarian reserve, the state of the uterus, and her partner’s sperm results, not from the infertility diagnosis alone.

How do you avoid OHSS during IVF?

OHSS (ovarian hyperstimulation syndrome) is a condition we may see during IVF, especially in women whose ovaries over-respond to the medicines. Today, with the right treatment plan, we can reduce that risk substantially.

The most important point for me is to identify the woman at risk before treatment starts. I am more careful in women with polycystic ovary syndrome, a high AMH level, or a large number of follicles on ultrasound. We do not give every patient the same dose. We set the starting dose according to ovarian reserve and the expected response, and we monitor follicle growth with ultrasound scans.

In high-risk patients we usually prefer an antagonist protocol. Using a GnRH agonist trigger before egg collection, instead of the classic hCG trigger injection, can markedly reduce the risk of OHSS. When needed, we freeze all the embryos and leave the transfer for a later cycle. This also lowers the risk of a pregnancy making OHSS worse. In some patients we can use additional protective medicines as well.

Of course, it is not possible to eliminate the risk completely. My approach is not to collect as many eggs as possible, but to obtain enough mature eggs while keeping the patient safe.

Does a high-grade embryo guarantee pregnancy?

No, unfortunately it does not. Of course, a very good grade from the embryology laboratory, such as 4AA or 5AA, is welcome news. But I make a point of telling my patients that these grades describe how the embryo looks under the microscope. They do not show that it is chromosomally healthy.

A 4AA embryo can have a chromosomal abnormality, for example, while a lower-graded embryo such as 3BB or 5BC can still lead to a healthy pregnancy. That said, appearance is not irrelevant. In general, good-quality blastocysts are more likely to implant and lead to a live birth. But that only tells us about probability.

The woman’s age, how many days the embryo took to develop, its chromosomal make-up, and uterine factors also affect the result. Even an embryo with a normal chromosome number after PGT-A (a genetic test of chromosome number on a few cells taken from the embryo) does not guarantee pregnancy.

That is why I do not think it is right to give a definite success percentage from embryo grade alone. For me, the grade helps us decide which embryo to transfer first; it is not a guarantee of pregnancy.

Conclusion

IVF planning is clearer when you separate what a test can measure from what it cannot, and when you compare outcomes using the same definitions.

What you are looking atWhat it helps estimateWhat it does not tell you
Age when the eggs are usedHow many eggs are likely, and the chromosome risk in the embryoThe result of one cycle
AMH and antral follicle countHow the ovaries may respond, and how many eggs might be collectedEgg quality, pregnancy, or live birth
Embryo gradeAppearance and stageWhether the chromosomes are normal
Clinic headline rateA group figureYour own chance, unless the age mix, treatment type, and outcome match your situation

The useful questions are usually practical: What is the main clinical problem? Which finding would change the plan? What outcome does the quoted rate describe? And what evidence supports any proposed add-on?

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.

Before getting in touch

Please note that certain services, such as sperm donation, egg donation, surrogacy and gender selection (without medical necessity), are not permitted under Turkish law.

We would like to inform you that our clinic strictly adheres to these regulations and does not offer any of these services.

Continue